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Objective. Mavrilimumab, a human monoclonal
antibody, targets granulocyte–macrophage colony-stimulat-
ing factor receptor a. We undertook to determine the long-
term safety and efficacy of mavrilimumab in rheumatoid
arthritis patients in 2 phase IIb studies (1071 and 1107)
and in 1 open-label extension study (ClinicalTrials.gov
identifier: NCT01712399).
Methods. In study 1071, patients with an inade-
quate response to disease-modifying antirheumatic drugs
(DMARDs) received mavrilimumab (30, 100, or 150 mg)
or placebo every other week plus methotrexate. In study
1107, patients with an inadequate response to anti–tumor
necrosis factor agents and/or DMARDs received 100 mg
mavrilimumab every other week or 50 mg golimumab
every 4 weeks plus methotrexate. Patients entering the
open-label extension study received 100 mg mavrili-
mumab every other week plus methotrexate. Long-term
safety and efficacy of mavrilimumab were assessed.
Results. A total of 442 patients received mavrili-
mumab (14 of 245 patients from study 1071, 9 of 70
patients from study 1107, and 52 of 397 patients from the
open-label extension study discontinued mavrilimumab
treatment throughout the studies). The cumulative safety
exposure was 899 patient-years; the median duration of
mavrilimumab treatment was 2.5 years (range 0.1–3.3
years). The most common treatment-emergent adverse
events (AEs) were nasopharyngitis (n = 69; 7.68 per 100
patient-years) and bronchitis (n = 51; 5.68 per 100
patient-years). At weeks 74 and 104, 3.5% and 6.2% of
patients, respectively, demonstrated reduction in forced
expiratory volume in 1 second, while 2.9% and 3.4% of
patients, respectively, demonstrated reduction in forced
vital capacity (>20% reduction from baseline to <80%
predicted). Most pulmonary changes were transient and
only infrequently associated with AEs. Mavrilimumab at
100 mg every other week demonstrated sustained efficacy;
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at week 122, 65.0% of patients achieved a Disease Activity
Score in 28 joints using the C-reactive protein level
(DAS28-CRP) of <3.2, and 40.6% of patients achieved a
DAS28-CRP of <2.6.
Conclusion. Long-term treatment with mavrili-
mumab maintained response and was well-tolerated with
no increased incidence of treatment-emergent AEs. Safety
data were comparable with those from both phase IIb
qualifying studies.
Rheumatoid arthritis (RA) is associated with a
high prevalence of comorbidities (1), including increased
risk of serious infections (2) and malignancies (1). This is
because of the immune system dysregulation intrinsic to
the disease and prolonged use of conventional immuno-
suppressive therapies and targeted biologic agents (2–4).
Granulocyte–macrophage colony-stimulating factor
(GM-CSF) is a proinflammatory cytokine involved in RA
pathogenesis (5,6). GM-CSF binds to GM-CSF receptor a
(GM-CSFRa), thereby reducing macrophage and neu-
trophil numbers and function in rheumatoid inflammatory
lesions (7,8). GM-CSF has a well-established role in hema-
topoiesis in vitro and in vivo, supporting neutrophilic gran-
ulocyte proliferation and differentiation (9,10); however,
there is little deficiency in resting hematopoiesis in gene-
targeted mice lacking GM-CSF or its receptor (11). This
suggests that GM-CSF is not required in vivo for resting
hematopoiesis. Patients with RA may still have anemia
(12) and occasionally neutropenia (13). In these cases, or
in the presence of infection, it is possible that GM-CSF is
necessary for adequate granulocyte production, and GM-
CSF inhibition may induce neutropenia (14).
GM-CSF is involved in lung homeostasis and pro-
motes alveolar macrophage proliferation (15,16), which
has a critical role in lung defense and surfactant homeosta-
sis (17) through catabolism of surfactant lipids and pro-
teins (18). Pulmonary alveolar proteinosis is a rare disease
characterized by alveolar surfactant accumulation (19).
Polyclonal anti–GM-CSF autoantibodies and mutations in
surfactant proteins or GM-CSFR are considered responsi-
ble for most cases of pulmonary alveolar proteinosis.
Mavrilimumab is a human monoclonal antibody
that blocks GM-CSFRa, acting as a competitive antagonist
of GM-CSF signaling (20). It has previously demonstrated
efficacy and an acceptable safety profile in RA patients in
a 12-week phase IIa study (21) and in 24-week phase IIb
studies (22,23) at dosages up to 150 mg every other week.
To evaluate the sustained safety and efficacy of
mavrilimumab (including the longitudinal assessment of
pulmonary function), we report the long-term (up to >3
years) safety profile in RA patients who participated in 2
phase IIb studies: study 1071 (22) and study 1107 (23).
Irrespective of initial treatment allocation, patients were
subsequently enrolled in an open-label extension study
(study 1109 [ClinicalTrials.gov identifier: NCT01712399])
and received mavrilimumab at 100 mg every other week.
PATIENTS AND METHODS
Study design. This report includes data from a phase II
open-label extension study (study 1109 [ClinicalTrials.gov iden-
tifier: NCT01712399]) and 2 qualifying phase IIb studies. Stud-
ies 1071 (EARTH EXPLORER 1 [ClinicalTrials.gov identifier:
NCT01706926]) (22) and 1107 (EARTH EXPLORER 2 [Clini-
calTrials.gov identifier: NCT01712399]) (23) were randomized,
double-blind, multicenter studies. In study 1071, 326 patients
with moderate-to-severe RA who had inadequate responses to
disease-modifying antirheumatic drugs (termed DMARD inad-
equate responders) received subcutaneous (SC) mavrilimumab
(30, 100, or 150 mg) or placebo every other week plus standard
therapy (methotrexate at 7.5–25.0 mg/week and folic acid at ≥5
mg/week). In study 1107, 138 patients who had a previous inad-
equate response to DMARDs and/or DMARD inadequate
responders for whom 1 or 2 anti–tumor necrosis factor (anti-
TNF) agents (excluding golimumab) had failed received SC
mavrilimumab at 100 mg every other week or golimumab at 50
mg every 4 weeks plus standard therapy (Figure 1). In study
1107, placebo was administered every other week to patients
receiving golimumab to maintain masking.
Patients who completed studies 1071 or 1107 or who
had inadequate clinical responses after week 12 were eligible to
enter the open-label extension study. All patients enrolled in the
open-label extension study received SC mavrilimumab at 100 mg
every other week plus standard therapy (Figure 1). Patients
received mavrilimumab at 100 mg as this was the highest, most
efficacious dose in a previous phase IIa study (21). At initiation
of the open-label extension study, no data from study 1071 were
available demonstrating improved efficacy and an acceptable
safety profile with mavrilimumab at 150 mg versus 100 mg.
All 3 studies were conducted in accordance with the
principles of the Declaration of Helsinki and the International
Conference on Harmonisation Guidelines for Good Clinical
Practice, and all were approved by the appropriate institutional
review board or independent ethics committee at each study
site. All patients provided written informed consent.
Inclusion and exclusion criteria for patients. Patients
were ages 18–80 years with moderate-to-severe adult-onset RA
according to the American College of Rheumatology/Euro-
pean League Against Rheumatism (ACR/EULAR) 2010 classi-
fication criteria (24), a Disease Activity Score in 28 joints (25)
using the C-reactive protein level (DAS28-CRP) of ≥3.2 at
screening, a DAS28 using the erythrocyte sedimentation rate
of ≥3.2 (26) on day 1, and ≥4 swollen joints at screening and
on day 1. Detailed inclusion and exclusion criteria for studies
1071 and 1107 are included in Supplementary Methods, avail-
able on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.40420/abstract.
Patients who completed the treatment period of the
qualifying study (1071 or 1107), or who did not have an adequate
response to the blinded investigational product at a predefined
time point in the qualifying study despite their initial randomiza-
tion, were eligible to enroll in the open-label extension study.
680 BURMESTER ET AL
However, ≤12 weeks had to elapse since their completion/with-
drawal visit in the qualifying study. Other key inclusion criteria
for the open-label extension study were receipt of a stable dose
of conventional DMARDs (chloroquine, hydroxychloroquine,
parenteral gold, sulfasalazine, or leflunomide) ≥4 weeks prior to
the first mavrilimumab dose, if patients were receiving treatment
with these drugs, and no evidence of clinically uncontrolled res-
piratory disease (confirmed by a pulmonologist who reviewed
patient data from respiratory assessments, including a chest
radiograph and pulmonary function tests performed at screen-
ing; the patient must have had forced expiratory volume in 1 sec-
ond/forced vital capacity [FEV1/FVC] ≥60% of predicted
values). Key exclusion criteria for the open-label extension study
included permanent discontinuation of investigational product
in either qualifying study, receipt of B cell–depleting therapies
during or after discontinuation from the qualifying studies, and
discontinuation of non–cell depleting biologic DMARDs within
8 weeks of day 1 of the open-label extension study. Stable
dosages of oral corticosteroids, analgesics, and nonsteroidal anti-
inflammatory drugs were permitted.
Analysis sets. The overall phase as-treated population
included all mavrilimumab-treated patients in studies 1071 or
1107 or in the open-label extension study. The open-label as-
treated population included all 100 mg mavrilimumab–treated
patients in the open-label extension study.
Safety analysis. Long-term safety of mavrilimumab was
assessed by evaluating treatment-emergent adverse events (AEs),
treatment-emergent serious AEs (SAEs), treatment-emergent
AEs of special interest (events of scientific and medical interest
specific to understanding of the investigational product and
requiring rapid communication with the sponsor [hepatic function
abnormality, acute and delayed hypersensitivity reactions, clini-
cally relevant pulmonary abnormality, neutropenia {absolute neu-
trophil count <1.0 9 109/liter}, malignancy, and infection]), and
laboratory measurements in the overall as-treated population.
The severity of all events was determined by the investigator.
Lung function abnormalities and pulmonary AEs were
assessed in the overall as-treated population. Pulmonary monitor-
ing was conducted throughout all studies, including serial standard-
ized lung function testing (FEV1/FVC), assessments of dyspnea
(using the Borg Dyspnea Index [27]), and chest radiographs. While
assessment of diffusing capacity for carbon monoxide (DLCO) was
performed in most patients included in the open-label extension
study, this test was not available at the start of the 2 qualifying ran-
domized studies due to initial standardization difficulties. There-
fore, baseline DLCO % predicted data were only collected in 48
patients from study 1107 and in no patients from study 1071, which
limited full interpretation of the results. A blinded Independent
Pulmonary Evaluation Committee (IPEC) adjudicated any patient
with a pulmonary abnormality (pulmonary AE/SAE and/or abnor-
malities on pulmonary function tests and DLCO considered clini-
cally relevant) for the presence of pulmonary alveolar proteinosis.
Efficacy analysis. The long-term clinical efficacy of mav-
rilimumab was evaluated as an exploratory objective. Efficacy
Figure 1. Designs of the phase IIb studies (1071 and 1107) and the open-label extension study (OLE). After week 24, patients enrolled in study
1071 or study 1107 were eligible for the open-label extension study and received mavrilimumab for up to a maximum of 3.3 years. After week 12,
patients enrolled in study 1071 or study 1107 who were not responding adequately to blinded study treatment were allowed to enter the open-label
extension study to receive mavrilimumab. Studies 1071 and 1107 were not conducted simultaneously. SC = subcutaneous; eow = every other week;
MTX = methotrexate.
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end points included proportions of patients achieving a DAS28-
CRP of <3.2 and <2.6 (overall as-treated population), propor-
tions of patients meeting the ACR 20% improvement criteria
(achieving an ACR20 response) (28) or achieving an ACR50 or
ACR70 response at weeks 74, 98, and 122 (as-treated population
in the open-label extension study), Clinical Disease Activity Index
(CDAI) (29) remission rates at weeks 74, 98, and 122 (as-treated
population in the open-label extension study), radiographic pro-
gression assessed by change from baseline in the modified Sharp/
van der Heijde score (SHS) (30) through week 74 (as-treated
population, only including patients from study 1071), and pa-
tient-reported outcomes (overall as-treated population), includ-
ing the Health Assessment Questionnaire disability index (31),
Short Form 36 health survey (32), and Functional Assessment of
Chronic Illness Therapy–Fatigue subscale (33).
Biomarker analysis. For a complete understanding of
mavrilimumab’s molecular mechanism of action, biomarkers
related to the GM-CSF pathway were analyzed in all patients
participating in study 1107 who enrolled in the open-label exten-
sion study. GM-CSF is believed to drive production of thymus
and activation–regulated chemokine (TARC)/CCL17 (34) and
macrophage-derived chemokine (MDC)/CCL22 (35), and serum
concentrations of CCL17 and CCL22 were suppressed by mavril-
imumab but not by golimumab in the qualifying 1107 study (36).
Serum CCL17/TARC and CCL22/MDC concentrations were
measured by enzyme-linked immunosorbent assay on days 1, 8,
29, 85, 169, 225, 253, 337, and 393 and are reported herein.
Statistical analysis. Safety and patient-reported out-
come data were summarized descriptively. Exposure-corrected
incidence rates for AEs and AEs of special interest were
used, expressed as number of patients experiencing an event
per 100 patient-years.
Proportions of patients achieving a DAS28-CRP of
<3.2 and <2.6 and ACR20/ACR50/ACR70 response rates were
calculated using the number of patients with an assessment at
each visit as the denominator and the number of responders as
the numerator. The CDAI was defined as the sum of the tender
joint count (using 28 joints), the swollen joint count (using
28 joints), the patient’s global assessment of disease activity
(on a 0–10-cm visual analog scale [VAS]), and the physician’s
global assessment of disease activity (on a 0–10-cm VAS).
CDAI remission was defined as a score of ≤2.8. Change in SHS
is presented using a cumulative incidence plot at week 74.
RESULTS
Patients. Randomization for study 1071 began
September 11, 2012; the last patient was evaluated Jan-
uary 29, 2014. In study 1107, patients were randomized
from March 19, 2013; the last patient was evaluated
February 6, 2015. The first patient entered the open-label
extension study February 11, 2013; the last patient visit
was completed December 30, 2015.
Across the 3 studies, 442 patients received mavrili-
mumab (overall as-treated population). Of these, 409
(92.5%) consented to participate in the open-label exten-
sion study; 12 were ineligible (primarily due to inclusion/
exclusion criteria) and did not receive treatment. There-
fore, the open-label as-treated population included 397
Table 1. Baseline demographic and disease characteristics of the
patients (as-treated population)*
Open-label extension study (n = 397)†
Demographic characteristics‡
Age, mean  SD years 51.1  11.2
Female, no. (%) 339 (85.4)
Race, no. (%)
White 364 (91.7)
American Indian/Alaska Native 29 (7.3)
Other§ 4 (1.0)
Disease characteristics‡
RA duration, mean  SD years 7.9  6.8
Prior biologic DMARD therapy, no. (%)¶ 100 (25.1)
Stopped because of loss of efficacy 47 (11.8)
Stopped because of safety/other# 53 (13.4)
MTX dosage, mean  SD mg/week 14.8  3.8
Corticosteroid dosage, mean  SD mg/week** 5.4  1.5
DAS28-CRP, mean  SD 4.3  1.6
HAQ DI score, mean  SD 1.2  0.6
Swollen joint count, mean  SD 7.2  7.9
Tender joint count, mean  SD 14.0  13.8
CRP, geometric mean mg/liter (CV %) 4.7 (170)
ESR, geometric mean mm/hour (CV %) 27.9 (62)
Studies 1071 and 1107 (n = 442)
Disease characteristics
DAS28-CRP, mean  SD 5.8  0.8
HAQ DI score, mean  SD 1.6  0.5
Swollen joint count, mean  SD 15.7  8.4
Tender joint count, mean  SD 26.3  12.6
CRP, geometric mean mg/liter (CV %) 6.0 (181)
ESR, geometric mean mm/hour (CV %) 36.8 (52)
Pulmonary disease characteristics
Concomitant pulmonary diseases, no. (%)††
Asthma 17 (3.8)
COPD 8 (1.8)
Other 21 (4.8)
Ever smoked, no. (%) 134 (30.3)
Current smokers, no. (%) 76 (17.2)
RF and ACPA positive, no. (%) 359 (81.2)
FEV1, mean  SD % predicted 93.9  14.7
FVC, mean  SD % predicted 94.0  14.6
DLCO, mean  SD % predicted (n)‡‡ 72.4  9.3 (48)
Borg Dyspnea Index score, mean  SEM 0.4  0.0
* RA = rheumatoid arthritis; MTX = methotrexate; DAS28-CRP =
Disease Activity Score in 28 joints using the C-reactive protein level;
HAQ DI = Health Assessment Questionnaire disability index; CV =
coefficient of variation; ESR = erythrocyte sedimentation rate; COPD
= chronic obstructive pulmonary disease; RF = rheumatoid factor;
ACPA = anti–citrullinated protein antibody; FEV1 = forced expiratory
volume in 1 second; FVC = forced vital capacity.
† An 8-week washout period occurred prior to the open-label exten-
sion study. Patients who did not have a response to mavrilimumab
were also included in the open-label extension study.
‡ Baseline values were obtained from predosing in studies 1071 and 1107.
§ Black, Asian, African American, Native Hawaiian, or other Pacific Islander.
¶ Patients were counted only once for each disease-modifying anti-
rheumatic drug (DMARD).
# Other reasons include discontinuation because of lack of initial
efficacy, expense of medication, or because the medication was given
only in a clinical trial.
** Derived from 234 of 397 patients (59%) who received concomitant
corticosteroids.
†† Clinically relevant uncontrolled pulmonary disease was an exclu-
sion criterion for all 3 studies.
‡‡ Diffusing capacity for carbon monoxide (DLCO) data were not col-
lected during study 1071 and were not collected in all patients in
study 1107; baseline values were available for 48 of 397 patients in
the open-label extension study.
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patients, of whom 345 (86.9%) were being treated at study
closure. Throughout the studies, 14 of 245 patients from
study 1071, 9 of 70 patients from study 1107, and 52 of 397
patients from the open-label extension study discontinued
mavrilimumab treatment (see Supplementary Figure 1,
http://onlinelibrary.wiley.com/doi/10.1002/art.40420/abstract).
A drug survival curve is shown in Supplementary Figure 2,
http://onlinelibrary.wiley.com/doi/10.1002/art.40420/abstract.
Baseline demographic and disease characteristics of the
patients are summarized in Table 1.
Safety analysis findings. Across the 3 studies,
patients had a cumulative mavrilimumab safety exposure
of 899 patient-years and a median treatment duration of
2.5 years (range 0.1–3.3 years). The majority of AEs were
mild or moderate, with 44 patients (10.0%) in the overall
as-treated population reporting a treatment-emergent AE
of grade ≥3 severity. The most frequently reported treat-
ment-emergent AEs and treatment-emergent SAEs in the
overall phase are shown in Table 2. There were no reports
of monocytopenia. Neutropenia was reported in 4 pa-
tients (2 with grade 1, 1 with grade 2, 1 with grade 3; 0.45
per 100 patient-years), and 14 patients reported serious
infections (1.56 per 100 patient-years). One event of neu-
tropenia (not recorded as an AE of special interest) was
considered serious and was associated with an SAE of uri-
nary tract infection that resolved with standard therapy.
Pulmonary events of special interest occurred in 83
patients (a full breakdown is shown in Supplementary
Table 1, http://onlinelibrary.wiley.com/doi/10.1002/art.40420/
abstract). The most frequent was bronchitis; 2 cases of
active pulmonary tuberculosis infection were reported (0.22
per 100 patient-years), and 1 was bacteriologically con-
firmed. Neither patient had active or latent tuberculosis at
screening or had previously received anti-TNF agents for
RA treatment. There were no cases of pulmonary alveolar
proteinosis or findings suggestive of pulmonary alveolar
proteinosis (confirmed by the IPEC).
Treatment-emergent AEs leading to discontinua-
tion were reported in 12 patients (3.0%) in the open-label
as-treated population (see Supplementary Table 2, http://
onlinelibrary.wiley.com/doi/10.1002/art.40420/abstract). Three
deaths were reported during the open-label extension study,
1 due to a car accident and 2 due to cardiopulmonary fail-
ure. One of the 2 patients with cardiopulmonary failure was
hospitalized for a few days before death (apparently to treat
sepsis subsequent to a biliary tract infection); the other
patient died suddenly. None of these deaths was considered
related to mavrilimumab treatment. There were no clinically
relevant shifts in laboratory values for the overall phase.
Pulmonary function and long-term pulmonary
safety analysis findings. The mean Borg Dyspnea Index
score in the overall as-treated population remained
unchanged at week 134 compared with week 74 (Table 3).
Similar dyspnea scores from baseline through week 134
were observed in the populations of patients who switched
to 100 mg mavrilimumab from 30 mg mavrilimumab,
150 mg mavrilimumab, 50 mg golimumab, or placebo.
Table 2. Summary of treatment-emergent AEs, treatment-emergent
SAEs, and treatment-emergent AEs of special interest (as-treated popu-
lation for the overall phase) in patients receiving 100 mg mavrilimumab
every other week (n = 442), with a cumulative mavrilimumab safety
exposure of 899 patient-years*
Summary of treatment-emergent AEs†
Patients reporting ≥1 treatment-emergent
AE, no. (%)
335 (75.8)
Treatment-emergent AEs in ≥15 patients, no.
(rate per 100 patient-years)
Nasopharyngitis 69 (7.68)
Bronchitis 51 (5.68)
Hypertension 38 (4.23)
Rheumatoid arthritis 44 (4.90)
Upper respiratory tract infection 38 (4.23)
Headache 31 (3.45)
Urinary tract infection 40 (4.45)
Influenza 29 (3.23)
Pharyngitis 20 (2.23)
Osteoarthritis 17 (1.89)
Diarrhea 21 (2.34)
Back pain 15 (1.67)
Gastroenteritis 15 (1.67)
Summary of treatment-emergent SAEs†
Patients reporting ≥1 treatment-emergent SAE,
no. (%)
60 (13.6)
Treatment-emergent SAEs in ≥2 patients, no.
(rate per 100 patient-years)
Osteoarthritis 4 (0.45)
Bronchitis 4 (0.45)
Rheumatoid arthritis 4 (0.45)
Anemia 3 (0.33)
Pulmonary tuberculosis 2 (0.22)
Gastroenteritis 2 (0.22)
Pneumonia 2 (0.22)
Urinary tract infection 2 (0.22)
Cardiopulmonary failure 2 (0.22)
Myocardial infarction 2 (0.22)
Cholelithiasis 2 (0.22)
Uterine leiomyoma 2 (0.22)
Deaths, no. (%) 3 (0.7)
Summary of treatment-emergent AEs of special
interest†
Patients reporting ≥1 treatment-emergent AE of
special interest, no. (%)
114 (25.8)
Treatment-emergent AEs of special interest, no.
(rate per 100 patient-years)
Hepatic function abnormalities 2 (0.22)
Hypersensitivity reactions 13 (1.45)
Serious infections 14 (1.56)
Malignancies 5 (0.56)
Neutropenia 4 (0.45)
Pulmonary events‡ 83 (9.24)
* Includes all patients exposed to mavrilimumab in studies 1071 and
1107 or in the open-label extension study. AEs = adverse events;
SAEs = serious AEs.
† Includes AEs with onset after the first mavrilimumab dosage.
‡ All were reviewed by an Independent Pulmonary Evaluation
Committee.
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A small proportion of patients experienced an
event defined as clinically relevant (>20% decrease from
baseline and <80% predicted) reduction in lung function
(FEV1 and FVC). At weeks 74 and 104, 3.5% and 6.2% of
patients, respectively, demonstrated reduction in FEV1,
while 2.9% and 3.4% of patients, respectively, demon-
strated reduction in FVC (>20% reduction from baseline
to <80% predicted) (Table 3). In most cases, these events
occurred at a single time point and were not associated
with a respiratory AE. Mean FEV1, FVC, and DLCO val-
ues remained within 5% of the mean baseline value for
patients treated during the randomized phases of the
phase IIb studies (Figure 2); however, baseline DLCO val-
ues were measured in a minority of patients (48 patients
and 0 patients in studies 1107 and 1071, respectively).
Efficacy analysis findings. In exploratory analyses,
patients demonstrated sustained efficacy with mavrilimu-
mab treatment. At week 122, a total of 117 patients
(65.0%) achieved low disease activity with a DAS28-CRP of
<3.2, and 73 patients (40.6%) achieved a DAS28-CRP of
<2.6 (overall as-treated population). DAS28-CRP <3.2 and
<2.6 response rates are shown in Figures 3A and B. Patients
treated with 100 mg mavrilimumab also demonstrated
sustained ACR20/ACR50/ACR70 responses (Figure 3C).
There was an increase in the number of patients with CDAI
remission over time in the open-label extension study (see
Supplementary Table 3, http://onlinelibrary.wiley.com/doi/
10.1002/art.40420/abstract). After 74 weeks, 54% of patients
demonstrated no radiographic progression (≤0.5-point
change in SHS compared with baseline values) (see Supple-
mentary Figure 3, http://onlinelibrary.wiley.com/doi/10.1002/
art.40420/abstract). The mean change in SHS from baseline
to week 74 was 1.40. Improvements from baseline in
patient-reported outcome end points were also observed
and maintained with mavrilimumab treatment (see Supple-
mentary Table 4, http://onlinelibrary.wiley.com/doi/10.1002/
art.40420/abstract).
Biomarker analysis findings. In study 1107, serum
TARC/CCL17 and MDC/CCL22 concentrations were
suppressed in patients treated with 100 mg mavrilimumab,
but not in patients treated with 50 mg golimumab (see
Supplementary Figure 4, http://onlinelibrary.wiley.com/
doi/10.1002/art.40420/abstract). These results were ob-
served in patients with an inadequate response to DMARDs
(≥1 failed regimen) and in those with an inadequate
response to anti-TNF (1–2 failed regimens, excluding goli-
mumab). After an 8-week washout period prior to the
open-label extension study, TARC/CCL17 and MDC/
CCL22 concentrations returned to baseline. However, in
the open-label extension study, mavrilimumab treatment
suppressed TARC/CCL17 and MDC/CCL22 concentrations
regardless of treatment received in study 1107.
DISCUSSION
We evaluated the safety of long-term mavrilimumab
treatment in patients with RA and demonstrated that it is
well tolerated, with most treatment-emergent AEs mild or
moderate in severity. Low incidences of neutropenia (0.90%;
0.45 per 100 patient-years) and serious infections (3.17%;
1.56 per 100 patient-years) were observed in the overall as-
treated population; there were no reports of monocytopenia.
Both reported deaths due to cardiopulmonary failure were
considered unrelated to mavrilimumab treatment. Previous
studies of mavrilimumab evaluated treatment for ≤24 weeks;
herein, we have shown that long-term mavrilimumab treat-
ment generated safety data comparable with those from the
phase IIb qualifying studies (22,23).
RA affects pulmonary function, and lung disease is
a major contributor to patient morbidity and mortality
(37,38). Disease may affect all lung areas, and the majority
of patients demonstrate low total lung capacity and FVC
(39). Pulmonary comorbidities may arise because of
chronic immune activation, increased susceptibility to infec-
tions (often related to immunomodulatory medications), or
direct toxicity from DMARDs or biologic therapies (40);
Table 3. Borg Dyspnea Index score and reductions from baseline in
pulmonary function test results (as-treated population for the overall
phase) in patients receiving 100 mg mavrilimumab every other week
(n = 442)*
Borg Dyspnea Index score (measure of breathlessness),
mean  SEM (n)
Week 12† NA
Week 74 0.3  0.0 (279)
Week 134 0.3  0.0 (58)
Pulmonary function test results‡
>20% reduction from baseline to <80% predicted
FEV1, no./total no. (%)
Week 12† 2/298 (0.7)
Week 74 8/231 (3.5)
Week 104 11/178 (6.2)
Week 130 1/29 (3.4)
>20% reduction from baseline to <80% predicted
FVC, no./total no. (%)
Week 12† 2/298 (0.7)
Week 74 7/239 (2.9)
Week 104 6/177 (3.4)
Week 130 0/32 (0.0)
* Includes all patients who received mavrilimumab in studies 1071 and
1107 or in the open-label extension study. NA = not available; FEV1 =
forced expiratory volume in 1 second; FVC = forced vital capacity.
† Between weeks 12 and 24, 3 patients receiving 150 mg mavrili-
mumab (3.8%), 8 patients receiving 100 mg mavrilimumab (9.4%), 12
patients receiving 30 mg mavrilimumab (14.8%), and 37 patients
receiving placebo (45.7%) transferred from study 1071 to the open-
label extension study because of lack of efficacy. Between weeks 12
and 24, 2 patients receiving 100 mg mavrilimumab (2.9%) and no
patients receiving 50 mg golimumab (0.0%) transferred from study
1107 to the open-label extension study because of lack of efficacy.
‡ Reported events do not necessarily overlap between time points.
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however, there are few long-term data concerning changes
in pulmonary function with progressive RA. Minor alter-
ations in pulmonary function have been observed in
patients receiving long-term low-dose methotrexate (41);
however, another study demonstrated that mean changes
in FEV1, FVC, and DLCO after 2 years of treatment with
Figure 2. Pulmonary function values over time (as-treated population for the overall phase). A, Forced expiratory volume in 1 second (FEV1). B,
Forced vital capacity (FVC). C, Diffusing capacity for carbon monoxide (DLCO). Dotted lines represent 5% above and below baseline values for
FEV1, FVC, and DLco. Between weeks 12 and 24, 3 patients receiving 150 mg mavrilimumab (3.8%), 8 patients receiving 100 mg mavrilimumab
(9.4%), 12 patients receiving 30 mg mavrilimumab (14.8%), and 37 patients receiving placebo (45.7%) transferred from study 1071 to the open-label
extension study (study 1109) because of lack of efficacy (<20% improvement in both the swollen and tender joint counts compared with day 1).
Between weeks 12 and 24, 2 patients receiving 100 mg mavrilimumab (2.9%) and no patients receiving 50 mg golimumab (0.0%) transferred from
study 1107 to study 1109 because of lack of efficacy. Following the decision of the sponsor to discontinue study 1109, patients’ exposure to a study
drug/placebo ranged from 2 to 156 weeks, depending on their date of entry and reason for withdrawal from the studies. For final time points in
which n ≤ 5, results were not shown because the number of patients was too low to enable meaningful interpretation. DLCO data were not collected
during study 1071, and during study 1107 baseline (BL) values were collected in only 48 patients.
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low-dose oral methotrexate were comparable with those
observed with placebo (42).
We showed that mean FEV1, FVC, and DLCO val-
ues remained within 5% of mean baseline values for the
overall phase; therefore, pulmonary deterioration was not
evident with long-term mavrilimumab treatment in addi-
tion to standard therapy. Full DLCO data that included
baseline values were only available for a limited
Figure 3. A and B, Proportions of patients with a Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) of <3.2 (A)
and proportions of patients with a DAS28-CRP of <2.6 (B) (data split by original randomized treatment; as-treated population for the overall phase).
C, Proportions of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) or achieving
an ACR50 or ACR70 response at weeks 74, 98, and 122 (as-treated population for the open-label extension [OLE] study). All visits with at least 5
patients are shown. From week 24, initial treatment was switched to 100 mg mavrilimumab every other week (eow). Q4W = every 4 weeks.
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proportion of patients. While patients with uncontrolled
pulmonary disease were excluded from all studies ana-
lyzed, those with less severe disease, such as asthma and
chronic obstructive pulmonary disease, were permitted.
Hence, although these studies may not completely repre-
sent the RA patient population, these data are representa-
tive of the majority of patients with RA.
Mavrilimumab competitively antagonizes GM-CSF
signaling through GM-CSFRa blockade. Abrogation of
GM-CSF signaling in alveolar macrophages may cause
surfactant metabolism abnormalities (43), accumulation
of which could cause pulmonary alveolar proteinosis, a
rare disease with potentially life-threatening consequences
(44). Our adjudicated individual data demonstrate that
long-term treatment with 100 mg mavrilimumab every
other week with concomitant methotrexate was not associ-
ated with pulmonary alveolar proteinosis. In the qualifying
studies, no clinically relevant differences in pulmonary
function were observed between different mavrilimumab
dosages and placebo up to week 24 in study 1071,
and between mavrilimumab and golimumab up to week
24 in study 1107. Long-term controlled comparisons of
the treatment regimens cannot be made beyond this
time point since all patients included in the open-label
extension study were treated with 100 mg mavrilimumab
every other week; however, it should be noted that a
clinically relevant and generally transient reduction in
FEV1 or FVC was only experienced by a small number
of patients beyond week 24. Furthermore, discontinua-
tion due to pulmonary events in the open-label phase
was low.
We observed clinically meaningful long-term effi-
cacy in patients receiving mavrilimumab for up to >3
years across many disease activity parameters. Biomar-
ker analyses demonstrated sustained suppression of 2
GM-CSF pathway–related protein markers following
mavrilimumab treatment, regardless of previous treat-
ment received. These results support data from previous
studies (22,23), confirming that TARC/CCL17 and
MDC/CCL22 specifically relate to the GM-CSF pathway
and indicating a potential benefit of inhibiting this path-
way in RA treatment.
This analysis had a number of limitations. The
extension phase was not randomized or controlled; there-
fore, we were unable to evaluate the long-term safety and
efficacy of mavrilimumab in comparison with a reference
population of patients with RA. Furthermore, the popula-
tion was reduced because of discontinuations from the 2
qualifying studies and ineligibility of patients who did not
meet inclusion criteria. However, the analysis conformed
to the EULAR recommendations for reporting rheuma-
tology clinical trial extension studies (45). The open-label
extension study dosage of 100 mg mavrilimumab every
other week was selected to be consistent with the highest
and most efficacious dosage in a previous phase IIa study
(21). However, data analysis from study 1071 (conducted
while the open-label extension study was ongoing) demon-
strated that 150 mg mavrilimumab was more effective in
DMARD inadequate responders (22), which suggests that
a suboptimal dosage was used in the open-label extension
study. Consequently, the study was discontinued.
To our knowledge, this study is unique, as multiple
pulmonary function tests were performed in a systematic,
long-term, longitudinal manner. No new safety signals or
evidence of clinically meaningful lung function deteriora-
tion were seen with long-term mavrilimumab treatment.
Long-term mavrilimumab treatment was also associated
with clear and sustained benefits in measures of RA dis-
ease outcomes. In light of the results from study 1071
(22), we advocate phase III studies with mavrilimumab
(at 150 mg every other week) in RA.
ACKNOWLEDGMENTS
The authors would like to thank the study investiga-
tors and the members of the IPEC (Professors Ian Bruce,
Hal Collard, Jonathan Goldin, Manny Kavuru, and Robert
Wise). The authors would like to acknowledge Wendy White
(MedImmune, Gaithersburg, MD) for her contribution to the
biomarker analysis and Kate Middleton (MedImmune, Cam-
bridge, UK) for assistance with reviewing the pulmonary and
general data. The authors would like to acknowledge Rebecca
Plant, MSc, of QXV Comms, an Ashfield Company, part of
UDG Healthcare, for medical writing support that was
funded by MedImmune.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Burmester had full access to all
of the data in the study and takes responsibility for the integrity of
the data and the accuracy of the data analysis.
Study conception and design. Burmester, McInnes, Kremer, Godwood,
Michaels, Guo, Close, Weinblatt.
Acquisition of data. Miranda, Vencovsky, Godwood, Albulescu, Guo,
Close.
Analysis and interpretation of data. Burmester, McInnes, Kremer,
Vencovsky, Godwood, Albulescu, Michaels, Guo, Close, Weinblatt.
ROLE OF THE STUDY SPONSOR
The study was funded by MedImmune. As many of the
authors are present or former employees of MedImmune, MedImmune
had a substantial role in the study design, collection of the data, analy-
sis and interpretation of the data, and the decision to submit the manu-
script for publication. MedImmune funded medical writing support
provided by QXV Comms, an Ashfield Company, part of UDG Health-
care. Publication of this article was not contingent upon approval by
MedImmune.
LONG-TERM SAFETY AND EFFICACY OF MAVRILIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS 687
ADDITIONAL DISCLOSURES
Author Godwood is an employee of Heptares Therapeutics.
Author Close is an employee of AstraZeneca.
REFERENCES
1. Van Onna M, Boonen A. The challenging interplay between
rheumatoid arthritis, ageing and comorbidities. BMC Muscu-
loskelet Disord 2016;17:184.
2. Listing J, Gerhold K, Zink A. The risk of infections associated
with rheumatoid arthritis, with its comorbidity and treatment.
Rheumatology (Oxford) 2013;52:53–61.
3. Singh JA, Cameron C, Noorbaloochi S, Cullis T, TuckerM, Christensen
R, et al. Risk of serious infection in biological treatment of patients
with rheumatoid arthritis: a systematic review and meta-analysis.
Lancet 2015;386:258–65.
4. Berghen N, Teuwen LA, Westhovens R, Verschueren P. Malignan-
cies and anti-TNF therapy in rheumatoid arthritis: a single-center
observational cohort study. Clin Rheumatol 2015;34:1687–95.
5. Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP.
G-CSF and GM-CSF as therapeutic targets in rheumatoid arthri-
tis. Nat Rev Rheumatol 2009;5:554–9.
6. Avci AB, Feist E, Burmester GR. Targeting GM-CSF in rheuma-
toid arthritis. Clin Exp Rheumatol 2016;34 Suppl 98:39–44.
7. Greven DE, Cohen ES, Gerlag DM, Campbell J, Woods J, Davis
N, et al. Preclinical characterisation of the GM-CSF receptor as
a therapeutic target in rheumatoid arthritis. Ann Rheum Dis
2015;74:1924–30.
8. Cook AD, Louis C, Robinson MJ, Saleh R, Sleeman MA, Hamilton
JA. Granulocyte macrophage colony-stimulating factor receptor a
expression and its targeting in antigen-induced arthritis and inflam-
mation. Arthritis Res Ther 2016;18:287.
9. Fleetwood AJ, Cook AD, Hamilton JA. Functions of granulo-
cyte-macrophage colony-stimulating factor. Crit Rev Immunol
2005;25:405–28.
10. Hamilton JA. Colony-stimulating factors in inflammation and
autoimmunity. Nat Rev Immunol 2008;8:533–44.
11. Zhan Y, Cheers C. Haemopoiesis in mice genetically lacking granu-
locyte-macrophage colony stimulating factor during chronic infection
with Mycobacterium avium. Immunol Cell Biol 2000;78:118–23.
12. Calisto Perez C, Leon R, Leon F, Ng SL. Rheumatoid arthritis
and anemia: the impact of different anti-inflammatory therapies
on hemoglobin levels: an observational study. Bol Asoc Med P R
2012;104:34–41.
13. Lazaro E, Morel J. Management of neutropenia in patients with
rheumatoid arthritis. Joint Bone Spine 2015;82:235–9.
14. Crotti C, Raimondo MG, Becciolini A, Biggioggero M, Favalli EG.
Spotlight on mavrilimumab for the treatment of rheumatoid arthri-
tis: evidence to date. Drug Des Devel Ther 2017;11:211–23.
15. Chen BD, Mueller M, Chou TH. Role of granulocyte/macro-
phage colony-stimulating factor in the regulation of murine alveo-
lar macrophage proliferation and differentiation. J Immunol
1988;141:139–44.
16. Akagawa KS, Kamoshita K, Tokunaga T. Effects of granulocyte-
macrophage colony-stimulating factor and colony-stimulating fac-
tor-1 on the proliferation and differentiation of murine alveolar
macrophages. J Immunol 1988;141:3383–90.
17. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA,
Trapnell BC. GM-CSF regulates alveolar macrophage differentia-
tion and innate immunity in the lung through PU.1. Immunity
2001;15:557–67.
18. Yoshida M, Korfhagen TR, Whitsett JA. Surfactant protein D
regulates NF-j B and matrix metalloproteinase production in
alveolar macrophages via oxidant-sensitive pathways. J Immunol
2001;166:7514–9.
19. Borie R, Danel C, Debray MP, Taille C, Dombret MC, Aubier M,
et al. Pulmonary alveolar proteinosis. Eur Respir Rev 2011;20:98–107.
20. Minter RR, Cohen ES, Wang B, Liang M, Vainshtein I, Rees G,
et al. Protein engineering and preclinical development of a GM-
CSF receptor antibody for the treatment of rheumatoid arthritis.
Br J Pharmacol 2013;168:200–11.
21. Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash
O, Vatutin M, et al. Efficacy and safety of mavrilimumab in sub-
jects with rheumatoid arthritis. Ann Rheum Dis 2013;72:1445–52.
22. Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M,
Vencovsky J, et al. A randomised phase IIb study of mavrilimumab,
a novel GM-CSF receptor a monoclonal antibody, in the treatment
of rheumatoid arthritis. Ann Rheum Dis 2017;76:1020–30.
23. Weinblatt M, McInnes I, Kremer J, Miranda P, Vencovsky J, Godwin
D, et al. EARTH EXPLORER 2, a phase IIb exploratory study eval-
uating efficacy and safety of mavrilimumab, a fully human granulo-
cyte-macrophage colony-stimulating factor receptor-a monoclonal
antibody, and the tumor necrosis factor antagonist golimumab in
rheumatoid arthritis. Ann Rheum Dis 2016;75:717–8.
24. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham
CO III, et al. 2010 rheumatoid arthritis classification criteria: an
American College of Rheumatology/European League Against Rheu-
matism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
25. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van
de Putte LB, van Riel PL. Modified disease activity scores that
include twenty-eight–joint counts: development and validation in
a prospective longitudinal study of patients with rheumatoid
arthritis. Arthritis Rheum 1995;38:44–8.
26. Van Gestel AM, Haagsma CJ, van Riel PL. Validation of
rheumatoid arthritis improvement criteria that include simplified
joint counts. Arthritis Rheum 1998;41:1845–50.
27. Borg GA. Psychophysical bases of perceived exertion. Med Sci
Sports Exerc 1982;14:377–81.
28. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D,
Goldsmith C, et al. American College of Rheumatology prelimi-
nary definition of improvement in rheumatoid arthritis. Arthritis
Rheum 1995;38:727–35.
29. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold
K, et al. Acute phase reactants add little to composite disease
activity indices for rheumatoid arthritis: validation of a clinical
activity score. Arthritis Res Ther 2005;7:R796–806.
30. Van der Heijde DM, van Riel PL, Gribnau FW, Nuver-Zwart IH,
van de Putte LB. Effects of hydroxychloroquine and sul-
phasalazine on progression of joint damage in rheumatoid arthri-
tis. Lancet 1989;1:1036–8.
31. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of
patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
32. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health sur-
vey: manual and interpretation guide. Boston: The Health Insti-
tute, New England Medical Center; 1993.
33. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober
J. Validation of the Functional Assessment of Chronic Illness
Therapy Fatigue Scale relative to other instrumentation in
patients with rheumatoid arthritis. J Rheumatol 2005;32:811–9.
34. Achuthan A, Cook AD, Lee MC, Saleh R, Khiew HW, Chang
MW, et al. Granulocyte macrophage colony-stimulating factor
induces CCL17 production via IRF4 to mediate inflammation.
J Clin Invest 2016;126:3453–66.
35. Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization pro-
files of human M-CSF-generated macrophages and comparison
of M1-markers in classically activated macrophages from GM-
CSF and M-CSF origin. Cell Immunol 2013;281:51–61.
36. Guo X, Wang S, Bay-Jensen AC, Karsdal MA, Godwood A,
Albulescu M, et al. Sustained suppression of peripheral biomark-
ers by mavrilimumab but not golimumab in anti-tumor necrosis
factor-inadequate responders: an exploratory analysis in the phase
IIb Earth Explorer 2 Clinical Trial [abstract]. Arthritis Rheumatol
2016;68 Suppl 10. URL: http://acrabstracts.org/abstract/sustained-
suppression-of-peripheral-biomarkers-by-mavrilimumab-but-not-
golimumab-in-anti-tumor-necrosis-factor-inadequate-responders-an-
exploratory-analysis-in-the-phase-iib-earth-explorer-2-clinical/.
688 BURMESTER ET AL
37. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc
2007;4:443–8.
38. Tsuchiya Y, Takayanagi N, Sugiura H, Miyahara Y, Tokunaga D,
Kawabata Y, et al. Lung diseases directly associated with rheumatoid
arthritis and their relationship to outcome. EurRespir J 2011;37:1411–7.
39. Kelly C, Iqbal K, Iman-Gutierrez L, Evans P, Manchegowda K.
Lung involvement in inflammatory rheumatic diseases. Best Pract
Res Clin Rheumatol 2016;30:870–88.
40. Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-
associated lung disease. Eur Respir Rev 2015;24:1–16.
41. Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP. Pulmo-
nary function in patients receiving long-term low-dose methotrex-
ate. Chest 1996;109:933–8.
42. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP.
Investigation of the chronic pulmonary effects of low-dose oral
methotrexate in patients with rheumatoid arthritis: a prospective
study incorporating HRCT scanning and pulmonary function tests.
Rheumatology (Oxford) 2002;41:262–7.
43. Antoniu SA. GM-CSF pathway correction in pulmonary alveolar
proteinosis. Expert Opin Biol Ther 2010;10:1357–65.
44. Khan A, Agarwal R. Pulmonary alveolar proteinosis. Respir Care
2011;56:1016–28.
45. Buch MH, Silva-Fernandez L, Carmona L, Aletaha D, Christensen
R, Combe B, et al. Development of EULAR recommendations
for the reporting of clinical trial extension studies in rheumatology.
Ann Rheum Dis 2015;74:963–9.
LONG-TERM SAFETY AND EFFICACY OF MAVRILIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS 689
